Drugs /

mk-5890

Back to Drugs List

Overview

NCI Definition [1]:
A humanized agonistic monoclonal antibody targeting the cell surface antigen CD27, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD27 agonistic monoclonal antibody MK-5890 targets and binds to CD27 on a variety of immune cell types, including most T-lymphocytes. This induces CD27-dependent signaling pathways and enhances T-cell-mediated responses, including the expansion of antigen-activated T-cells and the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes, memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation. It is overexpressed in certain tumor cell types.

Clinical Trials

View Clinical Trials for mk-5890

Mk-5890 has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating mk-5890, 1 is phase 1 (1 open) and 3 are phase 2 (3 open).

Non-small cell lung carcinoma, malignant solid tumor, and small cell lung carcinoma are the most common diseases being investigated in mk-5890 clinical trials [2].

Drug Details

Synonyms [2]:
anti-cd27 agonist monoclonal antibody mk-5890, anti-cd27 agonistic monoclonal antibody mk-5890, mk 5890, mk5890
Drug Target(s) [2]:
CD27
NCIT ID [1]:
C172056

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.